December 2019

Dear WIPO Re:Search Members and Friends,

How is intellectual property a driver of — and not a barrier to — solutions for neglected tropical diseases, malaria, and tuberculosis? Since 2011, pharmaceutical companies and research institutions have been answering that question by participating in the WIPO Re:Search Consortium. Through the sharing of existing drugs and industry know-how with talented researchers, our Members are finding novel uses of drugs for diseases of the world’s poor. In essence, Consortium Members are seizing the promise of open innovation.

To see what open innovation through WIPO Re:Search looks like in practice, take a look at our two newest publications. The first highlights WIPO Re:Search partnership stories from 2016 to 2019. The second publication looks at seven collaborations that have been advancing solutions for neglected infectious diseases along the product development pathway. Throughout these publications, we feature R&D partnerships made possible by our industry Members Eisai; GSK; Johnson & Johnson; Merck KGaA, Darmstadt, Germany; MSD*; Novartis, Pfizer, and Takeda.

We continue to expand Consortium activities in Latin America. Our newest WIPO Re:Search Member is the University of Puerto Rico, our second Member from the island Commonwealth.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA
New Member Announcement

**Welcome University of Puerto Rico – Our Second Member From the Island!**

The [University of Puerto Rico](https://www.upr.edu) (UPR) is the main public university system of Puerto Rico. It consists of 11 campuses and has approximately 58,000 students and 5,300 faculty members. UPR is the leader in research on the island and houses the majority of specialized equipment and facilities. As an important center of scientific activity for graduate students, UPR is the main producer of highly trained staff for corporations, industry, and government. Together with its research partners, which include the government sector, companies, industry, and community organizations, UPR is working to build a bright future for Puerto Rico.

---

**Partnership Hub Central**

**New NIH Tools Will Help Guide Clinical Researchers**

NIH has added new resources to its popular [NCCIH Clinical Research Toolbox](https://www.nih.gov). The web-based Toolbox contains templates, sample forms, protocols, and guidelines — including [Clinical Research Start Up](https://www.nih.gov) resources — to assist investigators in the development and conduct of high-quality clinical research studies. While the Toolbox is geared toward investigators funded by the National Center for Complementary and Integrative Health (NCCIH), many of the guidelines and templates should be helpful for all clinical investigators.

[Learn more in the NCCIH Research Blog](https://www.nih.gov)
New Publications

**WIPO Re:Search Partnership Stories 2016-2019**

BVGH brings to life the WIPO Re:Search portfolio of 155 R&D collaborations focused on improving the prevention, diagnosis, and treatment of some of the world’s most-devastating diseases. The stories show how global cross-sector collaborations are driving R&D for neglected infectious diseases.

Member companies featured include Eisai; GSK; Johnson & Johnson; Merck KGaA, Darmstadt, Germany; MSD*; Novartis, Pfizer, and Takeda.

[Read the publication](#)

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA

**WIPO Re:Search: Advancing Product Development for Neglected Infectious Diseases through Global Public-Private Partnerships**

This new publication features seven promising WIPO Re:Search drug development collaborations that have advanced through key R&D milestones.

[Read the publication](#)

BVGH FundFinder Featured Awards

**U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) Collaborative Awards**

CRDF Global is accepting proposals from joint U.S., Japan, and other Regional Asia-Pacific (APac)-based investigators working in the field of infectious disease and immunology research. The purpose of the USJCMSP collaborative awards is to foster new or expanded viral disease and immunology-focused biomedical research collaborations between researchers in Japan, the APac region, and U.S. investigators and institutions. It is expected that proposals will focus on questions of direct relevance to the APac region that will add to global knowledge about viral diseases and immunology. The USJCMSP continues to promote collaborations, especially to include early-stage and female scientists from around the region.
**Awards:** Up to US $60,000 each  
**Expected Number of Awards:** 6-8  
**Deadline:** Monday, March 16, 2020, 11:59 p.m. U.S. Eastern Time

### Additional Funding Opportunities

- [NTD-SC Research to Address the Challenges and Inequities Presented by Female Genital Schistosomiasis (FGS)](https://example.com) – Deadline: December 31, 2019  
- [EDCTP Senior Fellowships Plus 2019](https://example.com) – Deadline: February 1, 2020  
- [JSPS Research Fellowships in Japan (Extramural)](https://example.com) – Deadline: March 31, 2020

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:cathy.manner@example.com).

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 16-20, 2020</td>
<td><a href="https://example.com">Keystone Symposia: Tuberculosis: Immunity and Immune Evasion</a></td>
<td>Santa Fe, NM, USA</td>
</tr>
<tr>
<td>Feb. 20-23, 2020</td>
<td><a href="https://example.com">19th International Congress on Infectious Diseases</a></td>
<td>Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>Feb. 23-27, 2020</td>
<td><a href="https://example.com">Molecular Approaches to Malaria (MAM) 2020</a></td>
<td>Lorne, Victoria, Australia</td>
</tr>
<tr>
<td>June 1-12, 2020</td>
<td><a href="https://example.com">6th McGill Summer Institute in Infectious Diseases and Global Health (Now accepting applications)</a></td>
<td>Montreal, QC, Canada</td>
</tr>
</tbody>
</table>

*Known as EMD in the USA and Canada | **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.*